Recent Updates
Recently added Catalysts
OKYO Positive Sentiment Score: 70/100

OKYO Pharma Announces Purchase of Shares by Chief Medical Officer

Wednesday, July 22, 2026 1 min read
Key Takeaway: OKYO Pharma Limited announced that its Chief Medical Officer, Flavio Mantelli, purchased 20,000 shares at $1.40 each. The company is preparing to initiate a global Phase 3 clinical trial for its investigational therapy, urcosimod, aimed at treating neuropathic corneal pain. This trial will involve approximately 111 patients and is set to begin in the second half of the year.

Market Sentiment Analysis

POSITIVE FACTORS

  • Chief Medical Officer purchased shares, indicating confidence in the company.
  • Company is advancing towards a Phase 3 clinical trial for NCP treatment.
  • Focus on innovative therapies for eye diseases shows commitment to research.

Full Press Release Details

LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that OKYO Pharma’s Chief Medical Officer, Flavio Mantelli, MD, PhD, has purchased 20,000 of the Company’s ordinary shares on NASDAQ at $1.40 per share.

About OKYOPharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.
For further information, please visitwww.okyopharma.com.

For further inquiries:

OKYO Pharma LtdPaul SpencerBusiness Development and Investor Relations+44 (0) 207 495 2379Email:info@okyopharma.com

Frequently Asked Questions

Who is the Chief Medical Officer of OKYO Pharma?

The Chief Medical Officer of OKYO Pharma is Flavio Mantelli, MD, PhD.

What shares did OKYO's CMO purchase?

Flavio Mantelli purchased 20,000 ordinary shares of OKYO Pharma.

What is the price per share for the recent purchase?

The shares were purchased at $1.40 each.

What clinical trial is OKYO Pharma planning?

OKYO Pharma plans to initiate a Phase 3 clinical trial for urcosimod.

How many patients will be enrolled in the trial?

The trial will enroll approximately 111 patients.

Tags: OKYO Viatris Investor Conferences Healthcare OKYO Pharma Flavio Mantelli neuropathic corneal pain urcosimod clinical trial
Last updated: Jul 22, 2026